Search results
Lipid-lowering Therapies and Lp(a)
Author(s):
Stephen Nicholls
,
Adam J Nelson
Added:
2 weeks ago
Review Article
Author(s):
Kausik Ray
,
Upendra Kaul
,
Srinivasa Rao
,
et al
Added:
5 months ago
Lp(a) and Atherosclerosis
Author(s):
Annalisa Filtz
,
Leandro Slipczuk
,
Martha Gulati
Added:
2 months ago
Review Article
Author(s):
Matthias Bossard
Added:
6 months ago
TCT 2025 - The randomized VICTORY Study finds OCT-guided PCI involving lesion preparation with the OPN super-high-pressure non-compliant balloon is non-inferior to intravascular lithotropsy.Dr Matthias Bossard (Kantonsspital Lucerne, Lucerne, CH) joins us to discuss findings from the VICTORY Trial, a randomized, multicenter, non-inferiority comparison evaluating intravascular lithotripsy versus…
View more
Author(s):
Jonas Brinck
Added:
8 months ago
ESC Congress 2025 - Cascade screening proves to be an effective tool to identify more patients with elevated LP(a) levels.Dr Jonas Brinck (Karolinska Institute, SE) joins us to discuss findings from the LipoaScreen study, evaluating cascade screening for elevated lipoprotein(a) in relatives of patients with atherosclerotic coronary artery disease.This prospective study examined whether elevated…
View more
Author(s):
Michelle O'Donoghue
Added:
6 months ago
AHA Scientific Sessions 2025 - Dr Michelle O'Donoghue (Brigham and Women's Hospital, US) joins us to discuss the evolving understanding of the causal relationship between elevated lipoprotein(a) and atherosclerotic cardiovascular disease, and what this means for risk stratification and management strategies in clinical practice.Dr O'Donoghue begins by highlighting the importance for clinicians to…
View more
Added:
1 month ago
Source:
Arrhythmia Academy
Atrial fibrillation (AF), particularly when paroxysmal and asymptomatic, often goes undiagnosed, increasing the risk of stroke. A recent trial investigated whether remote screening with a commercially available smartwatch could enhance the detection of new-onset AF in an older population with an elevated risk of stroke.²Mechanism of ApplicationThe intervention utilised a smartwatch equipped with…
View more
Author(s):
Steven E Nissen
Added:
1 year ago
AHA Conference 2024 - Safety and efficacy outcomes of zerlasiran (Silence Therapeutics) in adults with elevated lipoprotein(a) at high risk of atherosclerotic cardiovascular disease events (ASCVD).Dr Steven Nissen (Cleveland Clinic, US) joins us onsite at AHA Conference to discuss the findings from ALPACAR (NCT05537571).ALPACAR is a phase 2, randomized, five-arm, placebo-controlled trial…
View more
AHA 24: The KRAKEN Trial
Author(s):
Stephen Nicholls
Added:
1 year ago
Video
Added:
1 month ago
Source:
Interventional Cardiology Review Journal
For patients with atrial fibrillation (AF) at high risk for both stroke and bleeding, catheter-based left atrial appendage closure (LAAC) was not found to be non-inferior to physician-directed best medical care, according to the results of the CLOSURE-AF trial.¹MethodologyThe multicentre, randomised CLOSURE-AF trial was conducted in Germany to assess the effectiveness of LAAC compared with best…
View more